Washington
Q3 2026Lobbying Q3 None last Q1 2026
YoY n/a vs Q3 2025
Members 0 90 days
Buys / sells 0 / 0 0 trades
HCRHealth Issues
8 quarters Open in Washington ›
RNAM
Avidity Biosciences, Inc.—
Median target
$72.00
range $72.00–75.00
Insider net
$0
no open-market trades · since Feb 27
New fund stakes
0
Q2 2026 13F · 1 exit
Filing reports
3
analyzed by SecBot
SecBot read BEARISH 3 reports · latest
Balance 1 bearish · 0 bullish · 1 mixed · 1 neutral oldest → newest, height = score
Avg score ·High conf. 2/3
Price
Daily candles with volume.
No data for this timeframe.
Signal stack
Where each data set points today.
- InsidersNO TRADES
No open-market buys or sells since Feb 27. Recent filings are awards, exercises and tax withholding.
- InstitutionsMIXED
Q2 2026: 0 added (0 new), 1 trimmed or exited.
- EstimatesFLAT
Current-quarter EPS estimate −$1.285 → −$1.305 over 90 days. 1 up, 0 down in 30 days.
Who's buying
13F· Q2 20260
new positions
1
exit
| Fund | Move | Value |
|---|---|---|
| NORGES BANK | EXIT | $0.00 |
| PRICE T ROWE ASSOCIATES INC /MD/ | EXIT | $0.00 |
| BlackRock, Inc. | EXIT | $0.00 |
| STATE STREET CORP | EXIT | $0.00 |
| FMR LLC | EXIT | $0.00 |
| MORGAN STANLEY | EXIT | $0.00 |
| BANK OF AMERICA CORP /DE/ | EXIT | $0.00 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | EXIT | $0.00 |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Nov 2025Recent actions
| Date | Firm | Rating |
|---|---|---|
| Nov 11, 2025 | Chardan Capital MAINTAIN | Neutral |
| Oct 29, 2025 | TD Cowen DOWNGRADE | Hold |
| Oct 28, 2025 | Chardan Capital DOWNGRADE | Neutral |
| Oct 28, 2025 | RBC Capital DOWNGRADE | Sector Perform |
| Oct 27, 2025 | Citigroup DOWNGRADE | Neutral |
| Oct 27, 2025 | Leerink Partners DOWNGRADE | Market Perform |
Insider ledger
Form 4$0
open-market buys or sells · since Feb 27
| Date | Insider | Type | Value |
|---|---|---|---|
| Feb 27, 2026 | LEVIN ARTHUR A Director | TO ISSUER | 13,489 sh |
| Feb 27, 2026 | LEVIN ARTHUR A Director | TO ISSUER | 144,000 sh |
| Feb 27, 2026 | LEVIN ARTHUR A Director | TO ISSUER | 115,500 sh |
| Feb 27, 2026 | LEVIN ARTHUR A Director | TO ISSUER | 12,500 sh |
| Feb 27, 2026 | Kaye Edward M. MD Director | TO ISSUER | 13,489 sh |
| Feb 27, 2026 | Kaye Edward M. MD Director | TO ISSUER | 22,000 sh |
| Feb 27, 2026 | Kaye Edward M. MD Director | TO ISSUER | 15,000 sh |
| Feb 27, 2026 | Kaye Edward M. MD Director | TO ISSUER | 11,323 sh |
Earnings setup
Estimates−$1.30
EPS estimate, this quarter
−2%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
−$1.28590d
−$1.28560d
−$1.28530d
−$1.2857d
−$1.305Now
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Next FY | -$3.80 | -$4.84–-$2.60 | -0.0% | $296.1M |
| Next Q | -$1.33 | -$1.61–-$1.01 | -1.1% | $2.3M |
| Current FY | -$5.05 | -$6.53–-$3.24 | -2.7% | $14.2M |
| Current Q | -$1.30 | -$1.59–-$0.98 | -1.6% | $2.3M |
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Aug 5, 2026 Earnings calendar
RNAM Q2 2026 Earnings Scheduled — 2026-08-05
Jun 30, 2026 Inst.
Jun 11, 2026 SEC NORGES BANK — EXIT
0 shares ($0.00)
Three mega-passive institutions (Vanguard, Fidelity, Morgan Stanley) collectively added $811.6M in RNAM shares during…
INST-CLUSTER — Impact 3/10
Mar 31, 2026 Inst.
Mar 9, 2026 SEC PRICE T ROWE ASSOCIATES — EXIT
0 shares ($0.00)
Avidity Biosciences, Inc. (RNAM) has filed Form 15-12G to terminate the registration of its common stock under Section…
15-12G — Impact 8/10
Three major institutions, including sovereign wealth fund Norges Bank and quant giant RenTech, initiated new positions…
INST-CLUSTER — Impact 7/10
Feb 27, 2026 Insider
LEVIN ARTHUR A disposed of 13,489 shares
Director
Feb 27, 2026 Insider
LEVIN ARTHUR A disposed of 144,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
SecBot reports
3 filings · 0 bullish · 1 bearish · 1 mixed · 1 neutral- NEUTRAL INST-CLUSTERJun 11, 2026
Three mega-passive institutions (Vanguard, Fidelity, Morgan Stanley) collectively added $811.6M in…
The absence of active-manager buying suggests the cluster is index-driven, not a conviction call. Monitor subsequent 13F filings for active fund participation or any catalyst that could explain…
- BEARISH 15-12GMar 9, 2026
Avidity Biosciences, Inc. (RNAM) has filed Form 15-12G to terminate the registration of its common…
Traders should expect RNAM shares to be delisted from Nasdaq imminently and move to OTC trading, if at all. With only one holder of record, the stock is effectively illiquid. Existing shareholders…
- MIXED INST-CLUSTERFeb 28, 2026
Three major institutions, including sovereign wealth fund Norges Bank and quant giant RenTech…
The sharp divergence — with passive giants exiting while active and sovereign investors enter — suggests a fundamental reassessment of RNAM's risk/reward. Traders should monitor upcoming clinical…
All RNAM filing & press-release reports (3)
- INST-CLUSTER reportJun 11, 2026
- 15-12G reportMar 9, 2026
- INST-CLUSTER reportFeb 28, 2026